Fig. 1
From: GSK-3β inhibits autophagy and enhances radiosensitivity in non-small cell lung cancer
GSK-3β expression in NSCLC specimens. GSK-3β expression was strong (a, b) in the bronchioles and alveoli, positive in well-differentiated NSCLC (c, adenocarcinoma and d, squamous cell carcinoma), and weak or negative in poorly differentiated NSCLC (e, adenocarcinoma and f, squamous cell carcinoma). A Kaplan-Meier survival analysis showed that patients with negative GSK-3β expression had a significantly better prognosis than those with positive expression (g)